Bernzott Capital Advisors lowered its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 0.7% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 26,779 shares of the medical equipment provider’s stock after selling 200 shares during the period. Bernzott Capital Advisors’ holdings in Zimmer Biomet Holdings were worth $3,438,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Enterprise Financial Services Corp increased its stake in shares of Zimmer Biomet Holdings by 0.3% in the second quarter. Enterprise Financial Services Corp now owns 2,646 shares of the medical equipment provider’s stock worth $340,000 after buying an additional 9 shares during the period. Alpha Windward LLC increased its stake in shares of Zimmer Biomet Holdings by 1.1% in the first quarter. Alpha Windward LLC now owns 1,651 shares of the medical equipment provider’s stock worth $202,000 after buying an additional 18 shares during the period. Sandy Spring Bank increased its stake in shares of Zimmer Biomet Holdings by 1.7% in the first quarter. Sandy Spring Bank now owns 1,222 shares of the medical equipment provider’s stock worth $149,000 after buying an additional 20 shares during the period. Parkside Financial Bank & Trust increased its stake in shares of Zimmer Biomet Holdings by 2.7% in the first quarter. Parkside Financial Bank & Trust now owns 839 shares of the medical equipment provider’s stock worth $102,000 after buying an additional 22 shares during the period. Finally, Cleararc Capital Inc. increased its stake in shares of Zimmer Biomet Holdings by 0.5% in the first quarter. Cleararc Capital Inc. now owns 4,897 shares of the medical equipment provider’s stock worth $598,000 after buying an additional 25 shares during the period. Institutional investors and hedge funds own 82.84% of the company’s stock.

Zimmer Biomet Holdings, Inc. (NYSE ZBH) opened at 113.08 on Thursday. The firm has a market capitalization of $22.86 billion, a PE ratio of 32.21 and a beta of 1.20. The firm’s 50-day moving average is $123.56 and its 200-day moving average is $121.24. Zimmer Biomet Holdings, Inc. has a 12 month low of $95.63 and a 12 month high of $133.49.

Zimmer Biomet Holdings (NYSE:ZBH) last announced its quarterly earnings results on Thursday, July 27th. The medical equipment provider reported $2.08 EPS for the quarter, missing the consensus estimate of $2.10 by $0.02. Zimmer Biomet Holdings had a net margin of 9.12% and a return on equity of 16.70%. The company had revenue of $1.95 billion for the quarter, compared to analyst estimates of $1.95 billion. During the same quarter last year, the business earned $2.02 EPS. The company’s revenue for the quarter was up 1.1% on a year-over-year basis. On average, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post $8.24 EPS for the current year.

The business also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 22nd will be issued a dividend of $0.24 per share. The ex-dividend date of this dividend is Thursday, September 21st. This represents a $0.96 annualized dividend and a yield of 0.85%. Zimmer Biomet Holdings’s dividend payout ratio (DPR) is presently 27.59%.

TRADEMARK VIOLATION NOTICE: This article was originally reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another publication, it was illegally copied and reposted in violation of U.S. & international trademark & copyright law. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/08/17/bernzott-capital-advisors-sells-200-shares-of-zimmer-biomet-holdings-inc-zbh.html.

A number of brokerages have recently commented on ZBH. Royal Bank Of Canada reiterated an “outperform” rating and set a $140.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Citigroup Inc. lifted their price target on shares of Zimmer Biomet Holdings from $108.00 to $130.00 and gave the stock a “neutral” rating in a report on Friday, June 9th. Jefferies Group LLC reiterated a “buy” rating and set a $148.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, June 30th. Wells Fargo & Company reiterated a “market weight” rating on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Finally, Piper Jaffray Companies reiterated a “buy” rating and set a $141.00 price target on shares of Zimmer Biomet Holdings in a report on Friday, July 14th. Four analysts have rated the stock with a sell rating, seven have issued a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the stock. Zimmer Biomet Holdings presently has a consensus rating of “Hold” and a consensus target price of $136.90.

In other Zimmer Biomet Holdings news, VP Tony W. Collins sold 16,986 shares of the stock in a transaction that occurred on Monday, July 31st. The stock was sold at an average price of $121.74, for a total transaction of $2,067,875.64. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Sang Yi sold 17,731 shares of the stock in a transaction that occurred on Monday, June 12th. The shares were sold at an average price of $124.56, for a total value of $2,208,573.36. The disclosure for this sale can be found here. Company insiders own 1.07% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.